Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil Regulatory Litigation May Affect Exclusivity, FDA “Ministerial” Role

Executive Summary

Ivax' declaratory judgment actions against Paxil maker GlaxoSmithKline could threaten Apotex' 180-day exclusivity on paroxetine
Advertisement

Related Content

FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
Paxil Generic Exclusivity To Be Shared By At Least Four Firms; Suits Continue
Paxil Generic Exclusivity To Be Shared By At Least Four Firms; Suits Continue
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Generic Paxil Launches Unlikely This Year, Par Says; Court, FDA Issues
FDA Patent Listing Review System Suggested By Paxil Appeals Court
Advertisement
UsernamePublicRestriction

Register

PS042246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel